The complementary role of imaging and tumor biomarkers in gynecological cancers: an update of the literature [PDF]
, 2018 Gynecological tumors, including endometrial, cervical and ovarian cancer, have increased in incidence over time. The widespread introduction of screening programs and advances in diagnostic imaging methods has lead to a progressive increase in ...
Anastasi, E +4 more
core +1 more source
The Tumor Cytosol miRNAs, Fluid miRNAs, and Exosome miRNAs in Lung Cancer. [PDF]
, 2014 The focus of this review is to provide an update on the progress of microRNAs (miRNAs) as potential biomarkers for lung cancer. miRNAs are single-stranded, small non-coding RNAs that regulate gene expression and show tissue-specific signatures ...
Haisheng eXu +4 more
core +2 more sources
Transthyretin Stimulates Tumor Growth through Regulation of Tumor, Immune, and Endothelial Cells [PDF]
, 2019 Early detection of lung cancer offers an important opportunity to decrease mortality while it is still treatable and curable. Thirteen secretory proteins that are Stat3 downstream gene products were identified as a panel of biomarkers for lung cancer ...
Ding, Xinchun +6 more
core +1 more source
Practical oncology, 2021 A huge amount of data obtained during last 30 years in multiple translational works allowed both to break particular tumor types into subgroups based on molecular markers but also to create pan-tumor subgroups based on particular markers. These evidence suggest the new approach to diagnostic and treatment algorithms should be implemented.
openaire +1 more source
Epigenetically inactivated RASSF1A as a tumor biomarker
Bosnian Journal of Basic Medical Sciences, 2020 RASSF1A represents one of the eight isoforms of the RASSF1 gene. RASSF1A is a tumor suppressor gene whose inactivation influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity and, most commonly, by promoter hypermethylation.
Dora Raos +5 more
openaire +7 more sources
Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. [PDF]
, 2013 Tumor heterogeneity is a limiting factor in cancer treatment and in the discovery of biomarkers to personalize it. We describe a computational purification tool, ISOpure, to directly address the effects of variable normal tissue contamination in clinical
Boutros, Paul C +5 more
core +2 more sources
Biomarkers for patients with Wilms tumor: a review
Frontiers in Oncology, 2023 Wilms tumor, originating from aberrant fetal nephrogenesis, is the most common renal malignancy in childhood. The overall survival of children is approximately 90%. Although existing risk-stratification systems are helpful in identifying patients with poor prognosis, the recurrence rate of Wilms tumors remains as high as 15%.
Hongfeng Zheng +3 more
openaire +3 more sources
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. [PDF]
, 2017 Background Circulating tumor cells (CTCs) and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in CTCs and tumor tissue were evaluated as prognostic or predictive markers of CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE) versus ...
Baeten, Kurt +19 more
core +1 more source
Current biomarkers of canine mammary tumors [PDF]
Acta Veterinaria Scandinavica, 2018 Mammary tumors are the second most common neoplasia in dogs. Due to the high similarity of canine mammary tumors (CMT) to human breast cancers (HBC), human biomarkers of HBC are also detectable in cases of CMT. The evaluation of biomarkers enables clinical diagnoses, treatment options and prognosis for bitches suffering from this disease.
Ilona Kaszak +5 more
openaire +4 more sources
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors [PDF]
Cancer Discovery, 2020 AbstractTumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing–based estimates of TMB have largely replaced whole-exome sequencing–derived TMB in the clinic.
Dan Sha +5 more
openaire +3 more sources